Furthermore, the efficacy of a second covalent inhibitor of KRAS G12C, adagrasib, was presented at the European Lung Cancer Virtual Conference in early 2021, where the multi-cohort phase I/II trial showed a 45% ORR in 51 advanced, typically pre-treated NSCLC patients [200]. This evidence concerns the gene KRAS and lung cancer.